Loading…
Lexeo Therapeutics, Inc. is projected to rise to $4.29 by 2027, a +4% move from its current price of $4.13. LXEO is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/2/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $4.00 | $4.13 | $4.26 | -0.03% |
| Aug 4 | $3.95 | $4.13 | $4.31 | -0.07% |
| Aug 5 | $3.91 | $4.13 | $4.35 | -0.10% |
| Aug 6 | $3.88 | $4.12 | $4.39 | -0.13% |
| Aug 7 | $3.85 | $4.12 | $4.42 | -0.17% |
| Aug 8 | $3.82 | $4.12 | $4.44 | -0.20% |
| Aug 9 | $3.80 | $4.12 | $4.47 | -0.23% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.80 | $4.12 | $4.47 | -0.23% |
| Week 2 | $3.66 | $4.11 | $4.61 | -0.47% |
| Week 3 | $3.56 | $4.10 | $4.72 | -0.70% |
| Week 4 | $3.48 | $4.09 | $4.81 | -0.93% |
| Week 5 | $3.40 | $4.08 | $4.90 | -1.16% |
| Week 6 | $3.34 | $4.07 | $4.97 | -1.39% |
| Week 7 | $3.28 | $4.06 | $5.04 | -1.62% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Lexeo Therapeutics, Inc., LXEO, is a clinical stage genetic medicine company focused on hereditary and acquired diseases with high unmet need in the United States.
Its product pipeline comprises LX2006, LX2020, LX2021, LX2022, LX1001, LX1020, and LX1021, all AAVrh10-based gene therapy candidates in various clinical and preclinical stages.
LX2006 is in phase 1/2 to treat friedreich ataxia cardiomyopathy; LX2020 is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for PKP2-ACM; LX2021 is in preclinical to deliver the coding sequence for connexin 43 (Cx43) for a group of inherited cardiac muscle disorders including ACM and some forms of dilated cardiomyopathy; LX2022 is in preclinical to deliver a functional TNNI3 gene for hypertrophic cardiomyopathy. LX1001, LX1020, and LX1021 have completed phase 1/2 clinical trials for the treatment of APOE4-associated Alzheimer's disease. The company has license agreements with Cornell University to conduct the LX1001 program and support the LX1004 program, plus a research collaboration with Cornell for preclinical development, and a third license for FA cardiomyopathy leveraging current and future clinical data from Cornell’s investigator-initiated work.
The company was founded in 2017 and is headquartered in New York, New York.
Lexeo Therapeutics, Inc. trades in the healthcare space as LXEO. Its current price is $4.13 and its market capitalization is $324.29M, with a market rank of 3378.
The price outlook is informed by a series of year-by-year forecast figures that show a path of gradual appreciation through mid-century, with an eventual multifold upside from 2026 onward. The forecast provides a 2026 baseline with an average price of $4.13 and a max of $5.23, rising to a 2030 average of $4.88 and a max of $7.27, and extending to a 2050 average of $15.44 with a max of $29.86.
These figures are estimates and should be interpreted in the context of market uncertainty. They are not guarantees of future performance.
A major floor 18.6% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 27.8% above — a clean break opens room to run.
A major ceiling 67.3% above — clearing it would confirm fresh momentum.
Key LXEO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of LXEO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.33 | Sell | $4.33 | Sell |
| MA 10 | $4.51 | Sell | $4.45 | Sell |
| MA 20 | $4.64 | Sell | $4.57 | Sell |
| MA 50 | $4.70 | Sell | $4.83 | Sell |
| MA 100 | $5.34 | Sell | $5.36 | Sell |
| MA 200 | $6.93 | Sell | $5.93 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 37.03 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -188.27 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.05 | Sell |
| ROC (12) | -12.87 | Sell |
| Bollinger %B (20,2) | -0.01 | Buy |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.22 | Sell |
| Awesome (5,34) | -0.36 | Sell |
| Ultimate (7,14,28) | 18.42 | Buy |
| Momentum (10) | -0.56 | Sell |
| Aroon Osc (25) | -68.00 | Sell |
| Hull MA (9) | 4.18 | Sell |
| ADX (14) | 11.74 | Neutral |
| ATR (14) | 0.15 | Info |
The 30-day picture is labeled BEARISH, with RSI(14) at 40. The stock trades relative to major moving averages, with SMA(50) at $4.70 and SMA(200) at $6.93.
Support is reported at $4.13 and resistance at $5.28. The reported 30-day range spans from a low of $3.37 to a high of $5.06. Annualized volatility is high at 60%, indicating a wider trading range in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $4.13 | $4.13 | $5.23 | 0% | Neutral | |
| $3.38 | $4.29 | $5.77 | +4% | Neutral | |
| $2.99 | $3.92 | $5.50 | -5% | Neutral | |
| $3.17 | $4.26 | $6.18 | +3% | Neutral | |
| $3.54 | $4.88 | $7.27 | +18% | Neutral | |
| $3.92 | $5.52 | $8.42 | +34% | Bullish | |
| $4.32 | $6.20 | $9.66 | +50% | Bullish | |
| $4.00 | $5.85 | $9.28 | +42% | Bullish | |
| $3.93 | $5.86 | $9.46 | +42% | Bullish | |
| $4.26 | $6.46 | $10.60 | +56% | Bullish | |
| $5.44 | $8.93 | $15.67 | +116% | Bullish | |
| $8.20 | $15.44 | $29.86 | +274% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $4.13 | $4.13 | $5.04 | +0.00% |
| September 2026 | $3.50 | $4.16 | $5.09 | +0.71% |
| October 2026 | $3.35 | $4.01 | $4.96 | -3.68% |
| November 2026 | $3.34 | $4.02 | $5.02 | +0.28% |
| December 2026 | $3.43 | $4.15 | $5.23 | +3.29% |
Click any year to see its month-by-month LXEO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Lexeo Therapeutics, Inc.'s 2026 outlook centres on $4.13, within a $4.13 to $5.23 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, LXEO could reach as high as $5.77, with a base case around $4.29 and support toward $3.38 — roughly +4% from $4.13. Price action looks broadly range-bound.
Expect LXEO to range from $2.99 to $5.50 through 2028. The $3.92 average target implies a -5% move from current prices. That is -9% versus the projected 2027 average. A consolidation phase looks the most probable path here.
The LXEO price prediction for 2029 points to an average of $4.26 (low $3.17, high $6.18) — a potential gain of +3% on today's $4.13. Price action looks broadly range-bound.
In 2030, LXEO is projected to trade between $3.54 and $7.27, averaging $4.88 — a potential gain of +18% from today's $4.13. That is up +15% on the projected 2029 average. A consolidation phase looks the most probable path here.
Lexeo Therapeutics, Inc.'s 2031 outlook centres on $5.52, within a $3.92 to $8.42 range. That is up +13% on the projected 2030 average. That marks a +34% change versus current levels. Momentum favours further upside here.
By 2032, LXEO could reach as high as $9.66, with a base case around $6.20 and support toward $4.32 — roughly +50% from $4.13. Buyers look set to stay in control over this stretch.
Expect LXEO to range from $4.00 to $9.28 through 2033. The $5.85 average target implies a +42% move from current prices. That is -6% versus the projected 2032 average. Momentum favours further upside here.
The LXEO price prediction for 2034 points to an average of $5.86 (low $3.93, high $9.46) — a potential gain of +42% on today's $4.13. Buyers look set to stay in control over this stretch.
In 2035, LXEO is projected to trade between $4.26 and $10.60, averaging $6.46 — a potential gain of +56% from today's $4.13. That is up +10% on the projected 2034 average. Momentum favours further upside here.
Lexeo Therapeutics, Inc.'s 2040 outlook centres on $8.93, within a $5.44 to $15.67 range. That is up +38% on the projected 2035 average. That marks a +116% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, LXEO could reach as high as $29.86, with a base case around $15.44 and support toward $8.20 — roughly +274% from $4.13. Momentum favours further upside here.
Investing $1,000 in LXEO today (≈ 242.130751 LXEO) could be worth
$3,737.82
+$2,737.82 (+274%) by 2050 · US Dollar
Based on the average projected LXEO price of $15.44 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in LXEOwould be worth at today's price.
$1,000 invested in LXEO on Jul 31, 2025 (≈ 211.41649 LXEO) would be worth
$873.15
-$126.85 (-12.7%) today · 0.87× · US Dollar
Based on a LXEO entry price of $4.73 vs. today's $4.13.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.66 | $886.27 | -11.4% |
| 1 month ago | $4.45 | $928.09 | -7.2% |
| 3 months ago | $5.77 | $715.77 | -28.4% |
| 6 months ago | $7.64 | $540.58 | -45.9% |
| 1 year ago | $4.73 | $873.15 | -12.7% |
| All time (2.7y) ago | $10.05 | $410.95 | -58.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our LXEO forecast.
Our base-case forecast reaches $8.30 around 2040.
Implied market cap at $8.30: $651.73M
Looking further out, the multi-year outlook shows a rise in the average price over time with notable upside in key milestones.
For 2030, the average is $4.88 with a min of $3.54 and a max of $7.27, yielding an ROI of 18.2% and a NEUTRAL sentiment. In 2031, the average climbs to $5.52 with a max of $8.42 and an ROI of 33.6% (NEUTRAL).
By 2040, the average is $8.93 and the max $15.67, with an ROI of 116.2% and a BULLISH sentiment. In 2050, the average reaches $15.44 and the max $29.86, delivering a ROI of 273.8% and a BULLISH sentiment.
These are forecast estimates, not guarantees, and should be considered within the broader context of market risk and sector-specific developments.
Tap a question to reveal the answer.
Year 2030 forecast: min $3.54, avg $4.88, max $7.27, ROI 18.2%, sentiment NEUTRAL.
Forecasts show a path from 2026 with avg $4.13 and ROI 0% to 2030 with ROI 18.2%, then higher ROIs by 2031 (33.6%), 2040 (116.2%), and 2050 (273.8%), with sentiment turning BULLISH in later years.
Yes. The 2050 forecast shows a max of $29.86, with an avg of $15.44 and ROI of 273.8%, and a BULLISH sentiment.
Current price is $4.13 and market cap is $324.29M; the rank is 3378.
In 2040, the min is $5.44, the avg is $8.93, the max is $15.67, with ROI of 116.2% and sentiment BULLISH.
Lexeo Therapeutics, Inc. Community Discussion
0Share your Lexeo Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.